This inventor holds 2 USPTO granted patents and 13 published patent applications. Top assignees: Elona Biotechnologies, Stelis Biopharma Private Limited. Active years: 2010-2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010-2018
Title: The Innovative Contributions of Ronald E. Zimmerman in Insulin Production
Introduction
Ronald E. Zimmerman, based in Greenwood, Indiana, has made significant strides in the field of biotechnology through his inventive contributions. With a total of two patents to his name, he has focused on developing advanced methods for insulin production and proinsulin constructs, which are crucial for therapeutic applications.
Latest Patents
Zimmerman's latest patents include innovative methods related to insulin production. These patents detail novel proinsulins and proinsulin analogs that possess specific amino acid and nucleic acid modifications. Such modifications aim to enhance the efficiency of insulin production processes. His work includes the formulation of proinsulin preparations that can be transformed into human insulin and insulin analogs, making them highly beneficial in therapeutic settings. Notably, the patents detail novel peptides of the C-peptide, as well as unique nucleic acid molecules encoding them, signifying a leap forward in insulin production methodologies.
Career Highlights
Throughout his career, Ronald E. Zimmerman has contributed to prominent companies in the biotechnology field, including Elona Biotechnologies and Stelis Biopharma Private Limited. His expertise in the development of insulin production technologies has made a lasting impact on these organizations, enabling them to advance their therapeutic offerings.
Collaborations
Zimmerman has collaborated with notable professionals in his field, including his coworkers David John Stokell and Michael Patrick Akers. These collaborations have likely enriched his work, providing diverse perspectives that enhance his innovative efforts in biopharmaceutical technologies.
Conclusion
Ronald E. Zimmerman's contributions to insulin production methods and proinsulin constructs represent a significant advancement in the field of biotechnology. His dedication to innovation continues to push the boundaries of therapeutic applications for diabetes management, benefiting countless individuals reliant on effective insulin therapies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile